This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
NVIDIA and Illumina have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NVIDIA and Illumina are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares
Charles River (CRL) Launches LVV-based Gene Therapy Platform
by Zacks Equity Research
Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.
Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Guardant Health (GH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up
by Zacks Equity Research
Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.
Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EXEL vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Expands Presence in India With New Facility
by Zacks Equity Research
Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Company News for Aug 11, 2023
by Zacks Equity Research
Companies in The News Are: DDS,MFC,ILMN,G
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.
Illumina (ILMN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 1,500% and 1.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Soars 3.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Illumina (ILMN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Illumina's (ILMN) Latest Launch to Boost Genomics Analysis
by Zacks Equity Research
Illumina's (ILMN) DRAGEN v4.2 is expected to improve the identification of genetic disease causes, drug discovery and population genomics.
LGND or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
LGND vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Here's Why You Should Retain Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) on solid long-term growth potential in the oncology space.
Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger
by Zacks Equity Research
Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.
LGND or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Illumina's (ILMN) New AI Tool to Predict Genomics Disease
by Zacks Equity Research
Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.
Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Repligen (RGEN) Up 2.7% Since Last Earnings Report?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23
by Zacks Equity Research
At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.